Innate Pharma stock tumbles after phase 1 trial data
Nov 18, 2026, 12:06 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Phase 1 trial results are newly disclosed clinical data that could alter the probability of future commercialization and thus expected future revenue; direction and magnitude of the impact are unclear from the headline alone.
AI summary
What happened, with direct paths to the underlying reporting
Innate Pharma published phase 1 trial data, and the stock fell after the disclosure.
Innate Pharma released phase 1 trial data that triggered a stock price tumble.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Innate Pharma and Sobi announced a strategic partnership to initiate TELLOMAK-3, the Phase 3 CTCL confirmatory trial for lacutamab, targeting accelerated approval in Sézary syndro…